chemotherapy

Open Access
Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience
TAKESHI FUKUDA, TAKUYA NODA, EIJIRO UCHIKURA, YUICHIRO AWAZU, REIKO TASAKA, KENJI IMAI, MAKOTO YAMAUCHI, TOMOYUKI ICHIMURA, TOMOYO YASUI and TOSHIYUKI SUMI

Anticancer Research July 2023, 43 (7) 3097-3105; DOI: https://doi.org/10.21873/anticanres.16481
You have access
Development of Real-world Data-based Medication Instruction Sheet for Acute Myeloid Leukemia Patients Receiving High-dose Cytarabine Consolidation Therapy
MAYAKO UCHIDA, SHIGERU ISHIDA, ERIKA MOCHIZUKI, NANA OZAWA, HIROKO YONEMITSU, HIDEKI OCHIAI, HANAE NAKAMURA, TAKEHIRO KAWASHIRI, KOJI KATO, NOBUAKI EGASHIRA, KOICHI AKASHI and ICHIRO IEIRI

Anticancer Research July 2023, 43 (7) 3321-3329; DOI: https://doi.org/10.21873/anticanres.16508
You have access
CDX2-positive Cancer of Unknown Primary With Upper-body Paralysis Was Dramatically Improved by Colorectal Cancer Chemotherapy
HIDEKO AKAGI, YUSAKU TANAKA, KOHEI WADA, MIANAMI TAKAHASHI, KOUDAI YOSHIDA and HIDEHARU DOMOTO

Anticancer Research June 2023, 43 (6) 2879-2884; DOI: https://doi.org/10.21873/anticanres.16458
Open Access
Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix
AI MIYOSHI, YUTAKA UEDA, TOMOKO KURITA, TADASHI KIMURA and KIYOSHI YOSHINO

Anticancer Research April 2023, 43 (4) 1397-1405; DOI: https://doi.org/10.21873/anticanres.16288
You have access
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
YASUSHI IDE, TAIGA OTSUKA, MOTOTSUGU SHIMOKAWA, FUTA KOGA, YUJIRO UEDA, JUNICHI NAKAZAWA, AZUSA KOMORI, SATOSHI OTSU, SHIHO ARIMA, MASARU FUKAHORI, AKITAKA MAKIYAMA, YUDAI SHINOHARA, SHOHEI UENO, HIROKI TAGUCHI, TAKUYA HONDA, TARO SHIBUKI, KENTA NIO, NORIO URESHINO, TOSHIHIKO MIZUTA, KENJI MITSUGI and TSUYOSHI SHIRAKAWA

Anticancer Research April 2023, 43 (4) 1817-1826; DOI: https://doi.org/10.21873/anticanres.16335
Open Access
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
MARINA ABE, TADAHIRO SHOJI, YOHEI CHIBA, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, FUMIAKI TAKAHASHI, TAKESHI AIDA and TSUKASA BABA

Anticancer Research March 2023, 43 (3) 1265-1272; DOI: https://doi.org/10.21873/anticanres.16273
You have access
Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer
KOJI TAKADA, SHINICHIRO KASHIWAGI, NOZOMI IIMORI, RIKA KOUHASHI, AKIMICHI YABUMOTO, WATARU GOTO, YUKA ASANO, YUKIE TAUCHI, KANA OGISAWA, TAMAMI MORISAKI, MASATSUNE SHIBUTANI, HIROAKI TANAKA and KIYOSHI MAEDA

Anticancer Research February 2023, 43 (2) 849-856; DOI: https://doi.org/10.21873/anticanres.16227
You have access
Factor Analysis of Intraoperative Bleeding Loss and its Impact on Prognosis in Breast Cancer
KOJI TAKADA, SHINICHIRO KASHIWAGI, NOZOMI IIMORI, RIKA KOUHASHI, AKIMICHI YABUMOTO, WATARU GOTO, YUKA ASANO, YUKIE TAUCHI, KANA OGISAWA, TAMAMI MORISAKI, MASATSUNE SHIBUTANI, HIROAKI TANAKA and KIYOSHI MAEDA

Anticancer Research January 2023, 43 (1) 191-200; DOI: https://doi.org/10.21873/anticanres.16149
You have access
Differences in Toxicity Between Ashkenazi and Sephardic Jews With Colon Cancer Treated With Adjuvant Chemotherapy: A Prospective Study
BARUCH BRENNER, YAEL STERN, NOA GORDON, TZIPORA FUKS, TAL GRANOT, JULIET DREYER and AARON SULKES

Anticancer Research January 2023, 43 (1) 239-245; DOI: https://doi.org/10.21873/anticanres.16155
You have access
Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer
KANAKO SUZUKI, SHINSUKE SASADA, YURI KIMURA, AKIKO EMI, TAKAYUKI KADOYA and MORIHITO OKADA

Anticancer Research December 2022, 42 (12) 5945-5949; DOI: https://doi.org/10.21873/anticanres.16104

Main menu

User menu

Search

chemotherapy

Pages